BriaCell Therapeutics names Richard Berman to board

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) appointed Richard Berman to its board of directors.

Mr. Berman has more than 35 years of experience in venture capital; senior management; and mergers and acquisitions. He is a director of several public and private life science companies including Advaxis (NASDAQ:ADXS), Cryoport (NASDAQ:CYRX), BioVie (OTCQB:BIVI), Immuron (ASX:IMC, NASDAQ:IMRN) and Cevolva Biotech.

“Richard is a successful business leader with almost four decades of experience and vast corporate relationships. He offers a great deal of business acumen, industry knowledge, strategy, and finance experience to the board,” Mr. Jamieson Bondarenko, chairman of Briacell, said in a statement.

Mr. Berman previously served as a director at Catasys (NASDAQ:CATS); and a chairman at Cevolva Biotech, MetaStat, and National Investment Managers. He was director, chairman & CEO of Apricus Biosciences (formerly Nexmed)

and Easylink Services (formerly Internet Commerce Corporation). Formerly, Mr. Berman worked at Goldman Sachs and served as senior VP of Bankers Trust Company.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.